Early research (Phase 1)Ended earlyNCT04510415
What this trial is testing
Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 2